secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-07-16T11:31:17+00:00
Accession:  0001171843-26-004708
Event type: litigation
Sentiment:  positive
Materiality: 0.90
Item codes: 1.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus receives $178M from Moderna settlement, files patent suits against Pfizer/BioNTech, plans $230M share repurchase
--------------------------------------------------------------------------------

- Received approximately $178M from Moderna as its share of noncontingent settlement payment on July 8, 2026.
- Filed three international patent infringement lawsuits against Pfizer/BioNTech in Canada and UPC seeking injunctions and damages.
- Entered termination agreement with Genevant for RSV agreement, with Genevant paying $1.0M termination fee.
- Approved one-time cash bonuses for CEO Lindsay Androski (1.5% of $178M) and CFO Tuan Nguyen (0.25% of proceeds).
- Plans to return up to $230M to shareholders via share repurchases in Q3 2026 after receiving dividend from Genevant parent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326004708/0001171843-26-004708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326004708/f8k_071626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer